Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVM16 + tislelizumab
- Development stage
- Phase 1
- Lead developer
- Everest Medicines
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intravenous
01
Overview
EVM16 + tislelizumab is an investigational combination therapy consisting of EVM16, a personalized therapeutic mRNA cancer vaccine, and tislelizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. EVM16 is developed by Everest Medicines using its proprietary AI-driven neoantigen prediction platform, EVER-NEO-1. It consists of patient-specific tumor neoantigens encapsulated in lipid nanoparticles (LNPs) and is administered via intramuscular injection to prime neoantigen-specific T-cell responses. Tislelizumab is an immune checkpoint inhibitor that blocks the PD-1 pathway to restore T-cell-mediated anti-tumor activity. The combination is being evaluated in the Phase 1 investigator-initiated trial EVM16CX01 (NCT06541639) for the treatment of advanced or recurrent solid tumors.
- Other names
- EVM16 + tislelizumabEVM16 and tislelizumabEVM-16 and tislelizumabEVM 16 and tislelizumabEVM16 in combination with tislelizumabEVM-16 in combination with tislelizumabEVM 16 in combination with tislelizumabEVM16 injection in combination with tislelizumabEVM-16 injection in combination with tislelizumabEVM 16 injection in combination with tislelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on EVM16 + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVM16 + tislelizumab.